login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
BIOMX INC (PHGE) Stock News
USA
- NYSEARCA:PHGE -
US09090D3017
-
Common Stock
0.28
USD
-0.04 (-11.5%)
Last: 11/18/2025, 7:00:34 PM
0.2899
USD
+0.01 (+3.54%)
After Hours:
11/18/2025, 7:00:34 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
PHGE Latest News, Press Relases and Analysis
All
Press Releases
4 days ago - By: Chartmill
- Mentions:
GTI
TAIT
CMCT
APLT
...
Wondering what's happening in today's after-hours session?
a day ago - By: Benzinga
- Mentions:
PACS
SLRX
ANVS
IMCC
...
12 Health Care Stocks Moving In Monday's Intraday Session
4 days ago - By: BiomX Inc
BiomX Inc. Announces 1-for-19 Reverse Stock Split
7 days ago - By: BiomX Inc
BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates
8 days ago - By: Benzinga
- Mentions:
SGMO
NNVC
REVB
CYCN
...
12 Health Care Stocks Moving In Monday's After-Market Session
14 days ago - By: BiomX Inc
BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections
a month ago - By: BiomX Inc
BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways
3 months ago - By: BiomX Inc
BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis
3 months ago - By: The Motley Fool
BiomX Posts Q2 Loss With 14% Cost Drop
3 months ago - By: BiomX Inc
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates
3 months ago - By: BiomX Inc
BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025
4 months ago - By: BiomX Inc
BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis
6 months ago - By: BiomX
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
Please enable JavaScript to continue using this application.